Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
The University of Melbourne · Walter and Eliza Hall Institute of Medical Research · +13 more institutions
Abstract
Detection of circulating tumor DNA (ctDNA) after resection of stage II colon cancer may identify patients at the highest risk of recurrence and help inform adjuvant treatment decisions. We used massively parallel sequencing-based assays to evaluate the ability of ctDNA to detect minimal residual disease in 1046 plasma samples from a prospective cohort of 230 patients with resected stage II colon cancer. In patients not treated with adjuvant chemotherapy, ctDNA was detected postoperatively in 14 of 178 (7.9%) patients, 11 (79%) of whom had recurred at a median follow-up of 27 months; recurrence occurred in only 16 (9.8 %) of 164 patients with negative ctDNA [hazard ratio (HR), 18; 95% confidence interval (CI),…
Citation impact
- FWCI
- 51.01
- Percentile
- 100%
- References
- 43
Authors
26- JTJeanne TieCorresponding
The University of Melbourne, Walter and Eliza Hall Institute of Medical Research, Western Health
- YWYuxuan WangCorresponding
Howard Hughes Medical Institute
- CTCristian Tomasetti
Johns Hopkins University, Johns Hopkins Medicine
- LLLu Li
Johns Hopkins University, Johns Hopkins Medicine
- SSSimeon Springer
Howard Hughes Medical Institute
Topics & keywords
- Colorectal cancer
- Stage (stratigraphy)
- Minimal residual disease
- Medicine
- Circulating tumor DNA
- Oncology
- Disease
- Cancer
- Good health and well-being